Turkey’s Most Advanced Crypto Trading Platform ICRYPEX Announces Joint Venture
30.4.2021 12:00:00 EEST | Business Wire | Press release
Focusing their investments on technology and financial technology, Hedef Girişim Sermayesi Yatırım Ortaklığı A.Ş. and İdealist Danışmanlık A.Ş is now partnering with ICRYPEX Cryptocurrency Exchange , one of the Turkey’s leading crypto trading platforms. Hedef Girişim Sermayesi Yatırım Ortaklığı and İdealist Danışmanlık acquire 30% of ICRYPEX Cryptocurrency Exchange.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210430005021/en/
Turkey’s most advanced crypto trading platform ICRYPEX announced joint venture (Photo: Business Wire)
ICRYPEX Cryptocurrency Exchange provides services to its customers with its 129 full time employees. ICRYPEX offers its investors a cutting-edge, super-fast and low commission multi-asset crypto trading platform while supporting crypto currency wallet services. ICRYPEX also makes a difference in the sector with its 24/7 phone support.
ICRYPEX Cryptocurrency Exchange stands out amongst other crypto exchanges with its unique technological infrastructure and the high transaction speed it provides to its investors. Developing its own technologies, ICRYPEX provides its investors with less than 10 milliseconds processing time, matching engines and blockchain investments.
Taking firm steps towards being a global brand, ICRYPEX has become the name and jersey sponsor of the Men's Basketball First Team of the Beşiktaş JK, which is one of the biggest clubs of Turkey in January 2021. ICRYPEX has made a first in the world and made sponsorship payment in Bitcoin.
ICRYPEX has also become Turkey's first cryptocurrency exchange listing AVAX chains developed by a Turkish computer scientist with Avalanche protocol.
ICRYPEX is also the first and only cryptocurrency exchange listing USD and USDT currencies simultaneously. Since February 2019 the company has focused on second phase developments and has developed its current products such as website, matching engines, storage-sweeping services in-house.
Hedef Girişim Sermayesi Yatırım Ortaklığı makes investments predominantly in the financial technology area. Ftech Labs Bilişim A.Ş., Fintables Bilişim Teknolojileri A.Ş., Eko Hesap Bilgi Teknolojileri A.Ş., İdealist Danışmanlık A.Ş., İnfo Yatırım Menkul Değerler A.Ş are among the companies in which Hedef Girişim has a share.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210430005021/en/
Contact information
Zuhal Circi
zuhal.circi@icrypex.com
+90 (850) 255 1079
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Energy Impact Partners Expands Nordic Investment Presence, Deepening Partnership with Nysnø Climate Investments3.8.2026 09:02:00 EEST | Press release
Energy Impact Partners LP ("EIP"), a global investment firm with over $5 billion in assets under management, today announced an expanded commitment to the Nordic energy innovation ecosystem, building on its longstanding strategic partnership with Nysnø Climate Investments ("Nysnø"). The expansion reflects EIP's conviction that Norway and the broader Nordic region will be a defining source of next-generation energy companies. It also marks a deepening of the firm's institutional relationship with Nysnø, an investor in EIP's $1.36 billion flagship fund. Together, the two firms aim to strengthen connectivity between Nordic founders and EIP's global network spanning venture capital, private equity, and credit. "Norway is one of the most sophisticated and forward-looking energy markets in the world," said Matthias Dill, CEO & Managing Partner, Europe at EIP. "We believe many of the defining companies of the next energy economy will emerge from ecosystems like Norway, where deep technical ex
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom